Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Publication date: Available online 1 March 2017
Source:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Author(s): Virginie Neirinckx, Hakan Hedman, Simone P. Niclou
Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.



http://ift.tt/2mcivDY